Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Mariette

Showing results (31-40 of 593) with videos related to

Pageof 60
Sort By:
Rheumatology (Oxford, England)|September 29, 2017
Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to doRaphaele Seror, Xavier Mariette
Nature Reviews. Rheumatology|February 9, 2018
B cells in the pathogenesis of primary Sjögren syndromeGaëtane Nocturne, Xavier Mariette
British Journal of Haematology|October 16, 2014
Sjögren Syndrome-associated lymphomas: an update on pathogenesis and managementGaetane Nocturne, Xavier Mariette
The New England Journal of Medicine|March 8, 2018
Primary Sjögren's SyndromeXavier Mariette, Lindsey A Criswell
The New England Journal of Medicine|July 5, 2018
Primary Sjögren's SyndromeXavier Mariette, Lindsey A Criswell
Joint Bone Spine|November 9, 2007
EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint diseaseCorinne Miceli-Richard, Xavier Mariette
Current Opinion in Rheumatology|July 31, 2010
Pathogenesis of Sjögren's syndrome and therapeutic consequencesXavier Mariette, Jacques-Eric Gottenberg
Annals of the Rheumatic Diseases|August 6, 2020
To immunosuppress: whom, when and how? That is the question with COVID-19Kevin L Winthrop, Xavier Mariette
Current Pharmaceutical Biotechnology|January 3, 2012
Primary Sjögren's syndrome: time for prospective cohortsJacques-Eric Gottenberg, Xavier Mariette
Nature Medicine|December 16, 2022
Using genetics to predict toxicity of cancer immunotherapyCaroline Robert, Stéphan Vagner, Xavier Mariette
Pageof 60

Showing results (31-40 of 593) with videos related to

Sort By:
Pageof 60
Rheumatology (Oxford, England)|September 29, 2017
Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to doRaphaele Seror, Xavier Mariette
Nature Reviews. Rheumatology|February 9, 2018
B cells in the pathogenesis of primary Sjögren syndromeGaëtane Nocturne, Xavier Mariette
British Journal of Haematology|October 16, 2014
Sjögren Syndrome-associated lymphomas: an update on pathogenesis and managementGaetane Nocturne, Xavier Mariette
The New England Journal of Medicine|March 8, 2018
Primary Sjögren's SyndromeXavier Mariette, Lindsey A Criswell
The New England Journal of Medicine|July 5, 2018
Primary Sjögren's SyndromeXavier Mariette, Lindsey A Criswell
Joint Bone Spine|November 9, 2007
EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint diseaseCorinne Miceli-Richard, Xavier Mariette
Current Opinion in Rheumatology|July 31, 2010
Pathogenesis of Sjögren's syndrome and therapeutic consequencesXavier Mariette, Jacques-Eric Gottenberg
Annals of the Rheumatic Diseases|August 6, 2020
To immunosuppress: whom, when and how? That is the question with COVID-19Kevin L Winthrop, Xavier Mariette
Current Pharmaceutical Biotechnology|January 3, 2012
Primary Sjögren's syndrome: time for prospective cohortsJacques-Eric Gottenberg, Xavier Mariette
Nature Medicine|December 16, 2022
Using genetics to predict toxicity of cancer immunotherapyCaroline Robert, Stéphan Vagner, Xavier Mariette
Pageof 60